Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10282734 | 0.88 | MTNR1A (0.51) | MTNR1AMTNR1BCA2MAPTTP53 | |
| SCHEMBL4134558 | 0.84 | CYP2A6 (0.51) | CA2MAPT | |
| SCHEMBL7744805 | 0.84 | MTNR1A (0.36) | MTNR1AMTNR1BCA2 | |
| SCHEMBL6003503 | 0.78 | MTNR1A (0.60) | MTNR1AMTNR1BCA2MAPTTP53 | |
| SCHEMBL8435339 | 0.72 | MTNR1A (0.61) | MTNR1AMTNR1BCA2MAPTTP53 | |
| SCHEMBL7749363 | 0.72 | CYP2A6 (0.52) | CA2MAPT | |
| SCHEMBL31164737 | 0.72 | MTNR1A (0.54) | MTNR1AMTNR1BCA2MAPTTP53 | |
| SCHEMBL10982992 | 0.72 | MTNR1A (0.54) | MTNR1AMTNR1BCA2MAPTTP53 | |
| SCHEMBL12314999 | 0.70 | CYP2A6 (0.54) | MTNR1AMTNR1BCA2MAPT | |
| SCHEMBL15466667 | 0.70 | MTNR1A (0.72) | MTNR1AMTNR1BCA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090639-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-07-28 | — | — | US | disclosed |
| US-8629281-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-14 | — | — | US | disclosed |
| US-8558011-B2 | Cold menthol receptor-1 antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-15 | — | — | US | disclosed |
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | COLBURN RAYMOND W (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184510-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | MTNR1A 28/4885MTNR1B 53/4885CA2 426/4885 |
| US-20120053347-A1 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | TRPM8, TRPM5, TRPM7 | MTNR1A 28/4885MTNR1B 53/4885CA2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.